At a glance
ClinicalIndex Comparison RecordPhase 2Unknown· 100 target
Drug / intervention
Etoposidedrug
Likely dose
Etoposide 25mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Single-arm, Multicenter Study of Etoposide Monotherapy in Treating Patients With Recurrent or Metastatic Breast Cancer
In Brief
A Phase 2 clinical trial evaluating Etoposide for Breast Cancer. Targeting 100 participants across 14 sites.
Detailed Summary
The purpose of this study is to determine whether Etoposide Monotherapy is effective and safe in the treatment of recurrent or metastatic breast cancer in Chinese female patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesChina
CollaboratorsPeking University Cancer Hospital & Institute, Peking Union Medical College Hospital, Beijing Chao Yang Hospital, China-Japan Friendship Hospital, Beijing Hospital of the Ministry of Health, The First Affiliated Hospital of Dalian Medical University, The Second Affiliated Hospital of Harbin Medical University, Zhejiang Cancer Hospital, Henan Cancer Hospital, Guangxi Cancer Hospital, Shanghai Putuo District Center Hospital, International Peace Maternity and Child Health Hospital, Xinjiang Medical University
Timeline
Phase 2UnknownOverdue
201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2011
First PostedDec 2011
Primary CompletionJun 2014
Study CompletionJun 2015
TodayJul 2026
First PostedDec 15, 2011
Enrollment StartDec 1, 2011
Primary CompletionJun 1, 2014
Study CompletionJun 1, 2015
TodayJul 1, 2026
Enrollment to primary: 2.5 yearsPosted 14.5 years ago
Interventions
Etoposidedrug
Lastet (Etoposide Capsules, 25mg\*40 capsules/box), manufactured by Nippon Kayaku Co., Ltd.